Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
clinical trials
life sciences
national blog main
boston blog main
boston top stories
san francisco blog main
boston
fda
national top stories
rare disease drugs
cancer
cancer drugs
deals
dyne therapeutics
investing
myotonic dystrophy type 1
new york blog main
san diego blog main
san francisco top stories
third rock ventures
acute migrane
akouos
ally bridge group
amgen
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
bain capital
bausch health
big data analytics
biotech ipos
black diamond therapeutics
blackrock
bladder cancer
bluebird bio
blueprint medicines
breast cancer
What
drug
7
×
ipo
7
×
medicines
therapeutics
biotech
genetic
cancer
companies
company
developing
diseases
dyne
ipos
lead
leading
million
muscle
new
raised
rare
research
targets
activity
affects
ago
americans
analysis
approved
bio
biotechs
black
bring
brings
clinic
considering
data
date
days
despite
develop
Language
unset
Current search:
ipo
×
drug
×
biotech
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs